Ginwa Enterprise Group Inc
SSE:600080
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Ginwa Enterprise Group Inc
SSE:600080
|
2.9B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
978.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
273B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
150.2B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
96B EUR |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Ginwa Enterprise Group Inc
Glance View
Ginwa Enterprise (Group) Inc. engages in the manufacture and distribution of pharmaceuticals. The company is headquartered in Xi'An, Shaanxi and currently employs 607 full-time employees. The firm's main product is jintiange capsules, used for treatment of osteoporosis. The firm provides products in various forms, including tablets, oral solutions, capsules and others. In addition, the Company involves in the provision of hotel services and operation of rental business. Through its subsidiaries, the Company is involved in hotel operation business, wholesale and retail of pharmaceuticals and medical devices, as well as television drama production businesses and others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Ginwa Enterprise Group Inc is 14.2%, which is above its 3-year median of 3.5%.
Over the last 3 years, Ginwa Enterprise Group Inc’s Net Margin has increased from -1.7% to 14.2%. During this period, it reached a low of -7.6% on Dec 31, 2023 and a high of 14.2% on Oct 30, 2025.